囊性水瘤的围产期结局:系统综述与Meta分析
该系统综述与Meta分析检索截至2024年3月18日的观察性队列研究,纳入57项研究共4693例产前超声诊断的囊性水瘤病例。合并遗传学诊断率为55%,主要结构畸形率为42%,20%的病例在孕期消退或缓解;结论指出囊性水瘤与常见三体及特纳综合征强相关,但存在非非整倍体遗传诊断,约40%伴其他结构畸形。
要点
- 囊性水瘤合并遗传学诊断率为55%,其中特纳综合征21%、21三体17%、18三体10%、13三体3%、其他遗传诊断5%。
- 主要结构畸形合并率为42%;在伴额外结构畸形的病例中,16%未发现遗传学诊断。
- 20%的囊性水瘤在孕期消退或缓解;结论建议进一步研究结局修饰因素以利于更精准的患者咨询。
核心结论
- 囊性水瘤与常见三体及特纳综合征强相关,但部分病例为非非整倍体遗传诊断。
- 约40%的病例合并其他结构畸形,详细早孕期解剖超声可能有助于发现这些畸形。
- 需进一步研究囊性水瘤结局的修饰因素,以实现更准确和个体化的患者咨询。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase和Web of Science Core Collection数据库,检索时间从建库至2024年3月18日。
- 纳入标准为全文英文观察性队列研究,报告产前超声诊断囊性水瘤胎儿的任何妊娠及出生后结局。
- 共纳入57项研究,包含4693例囊性水瘤病例。
- 主要结局为遗传学诊断发生率和主要结构畸形发生率;次要结局包括围产期丢失、终止妊娠、囊性水瘤消退、活产率和正常出生后结局。
主要发现
- 遗传学诊断合并患病率(56项研究,3837例胎儿)为55%(95% CI,0.51-0.58)。
- 特定非整倍体合并患病率:特纳综合征21%,21三体17%,18三体10%,13三体3%,其他遗传诊断5%。
- 主要结构畸形总体合并患病率(30项研究,1987例胎儿)为42%。
- 在16项研究(1815例胎儿)中,囊性水瘤合并额外结构畸形且未发现遗传学诊断者占16%。
- 20%的囊性水瘤在孕期消退或缓解;以分隔作为诊断标准的研究及仅关注早孕期囊性水瘤的研究结果与总体结局一致。
关键数值与推荐
- 主要结局:遗传学诊断合并患病率55%(95% CI,0.51-0.58;56项研究,3837例胎儿)。
- 主要结构畸形合并患病率42%(30项研究,1987例胎儿)。
- 囊性水瘤合并额外结构畸形且无遗传学诊断者占16%(16项研究,1815例胎儿)。
- 囊性水瘤孕期消退或缓解率为20%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步研究囊性水瘤结局的修饰因素,以实现更准确和个体化的患者咨询。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this systematic review and meta-analysis was to describe the perinatal outcomes and modifiers of antenatally diagnosed cystic hygroma (CH). DATA SOURCES: The PubMed, Embase and Web of Science Core Collection databases were searched from inception until March 18, 2024. STUDY ELIGIBILITY CRITERIA: Full-text English-language observational cohort studies reporting any pregnancy and postnatal outcomes for fetuses with a CH diagnosed on prenatal ultrasound were included in this study. METHODS: The primary outcome was the incidence of genetic diagnosis and incidence of major structural anomalies. Secondary outcomes included the incidence of perinatal loss, termination of pregnancy, CH resolution, live birth rate and normal postnatal outcomes. Stratified analyses were conducted of cases diagnosed in the first trimester as well as all cases with septations as part of diagnostic criteria. Pooled proportions were calculated for the different outcomes. RESULTS: Fifty-seven studies met inclusion criteria (including 4693 cases of CH); these were cohort studies that included any of our primary search outcomes. The pooled prevalence of genetic diagnosis (56 studies, 3837 fetuses) was 55% (95% CI, 0.51-0.58). For specific aneuploidies, the pooled prevalence was 21% for Turner syndrome, 17% for Trisomy 21, 10% for Trisomy 18, 3% for Trisomy 13, and 5% for other genetic diagnoses. The overall pooled prevalence of major structural anomalies (30 studies, 1987 fetuses) was 42%; across 16 studies (1815 fetuses), 16% of fetuses with CH and an additional structural abnormality had no identified genetic diagnosis. Furthermore, 20% of all CH regressed or resolved during the pregnancy. The findings from the studies that that defined CH by the presence of septations, as well as those focusing solely on first trimester CH were consistent with the overall outcomes. CONCLUSIONS: Our findings confirm that while CHs have a strong association with common trisomies and Turner syndrome, there is a proportion of cases with nonaneuploidy genetic diagnoses. Forty percent of cases are also associated with other structural anomalies that may be able to be elicited with a detailed first trimester anatomic ultrasound. Further studies should explore modifiers of CH outcomes to allow for more accurate and tailored patient counseling.
引用
- Wang MJ, Bazan M, Hsieh T, et al. Perinatal outcomes of cystic hygroma: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2025. PMID: 40389136. doi:10.1016/j.ajogmf.2025.101704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。